Promises
2 promises
Promise Tracker
0 delivered, 0 close, 2 missed.
View Promises →
Aurobindo Pharma Limited — Q1 FY25
Aurobindo Pharma reported a solid Q1 FY25 with revenue of INR 7,567 crore (+10% YoY) and PAT of INR 919 crore (+61% YoY), driven by strong performance in Europe (EUR 221 million, +8% YoY) and growth markets (+49% YoY).
bullish
medium
✓ Verified against BSE filing
2-Minute Summary
✦ AI-Generated from Full Transcript
Aurobindo Pharma reported a solid Q1 FY25 with revenue of INR 7,567 crore (+10% YoY) and PAT of INR 919 crore (+61% YoY), driven by strong performance in Europe (EUR 221 million, +8% YoY) and growth markets (+49% YoY). US formulation revenue was $426 million (+12% YoY), supported by volume gains and new launches, though injectable sales were impacted by remediation at Eugia Unit III. EBITDA margin of 21.4% was in line with guidance, with one-off costs of ~$9 million for remediation and Pen-G ramp-up. Management reiterated FY25 EBITDA margin target of 21%-22% and expects improvement from Q2 as remediation costs decline and Pen-G ramps from October. Europe is on track to exceed EUR 880 million for FY25. Key risk: further delays in Pen-G ramp-up or injectable remediation could pressure margins.
ऑरोबिंदो फार्मा ने पहली तिमाही में अच्छा प्रदर्शन किया। कंपनी की कमाई 7,567 करोड़ रुपये रही, जो पिछले साल से 10% ज्यादा है। मुनाफा 919 करोड़ रुपये रहा, जो 61% बढ़ा। यूरोप और दूसरे बाजारों में अच्छी बिक्री से यह संभव हुआ। अमेरिका में दवाओं की बिक्री 426 मिलियन डॉलर रही, जो 12% ज्यादा है। हालांकि, इंजेक्शन वाली दवाओं की बिक्री पर फैक्ट्री की मरम्मत का असर पड़ा। कंपनी का मुनाफा मार्जिन 21.4% रहा, जो उसके लक्ष्य के अनुसार है। कंपनी को उम्मीद है कि अक्टूबर से मरम्मत का खर्च कम होगा और पेन-जी दवा का उत्पादन बढ़ेगा, जिससे मार्जिन में सुधार होगा। यूरोप में इस साल 880 मिलियन यूरो से ज्यादा की बिक्री का लक्ष्य है। सावधानी: अगर पेन-जी का उत्पादन देर से शुरू हुआ या फैक्ट्री की मरम्मत में देरी हुई, तो मुनाफा कम हो सकता है।
Promises0 met · 2 missedRisks4 trackedTranscriptfull text
Research workspace
Focused Modules
Risks
4 risks
Risk Intelligence
Pen-G ramp-up delays
View Risks →
Transcript
Full text
Call Transcript
Full transcript text is available on this route.
Read Transcript →Quarter Snapshot
US Formulation Revenue
$426M
+12% YoY
US formulation grew 12% YoY to $426M, driven by volume gains and new product launches.
Europe Formulation Revenue
EUR 221M
+8% YoY
Europe revenue grew 8% YoY to EUR 221M, on track to exceed EUR 880M for FY25.
Growth Markets Revenue
INR 709 Cr
+49% YoY
Growth markets revenue surged 49% YoY to INR 709 Cr, driven by new geographies.
Global Injectable & Specialty Sales
$142M
+16% YoY
Global injectable and specialty sales grew 16% YoY to $142M, despite remediation impact.
What Changed vs Last Quarter
NEW
Europe revenue to exceed EUR 880 million for FY25
Europe formulations on track to achieve EUR 880 million+ for FY25, with potential to reach EUR 900 million.
NEW
Pen-G plant ramp-up from October 2024
Pen-G plant expected to ramp up significantly from October 2024, with 80% capacity utilization targeted by Q3.
NEW
China plant commercialization from Q3 FY25
China plant expected to start commercial production from Q3 FY25, with ramp-up from Q4 FY25.
UPDATED
FY25 EBITDA margin target of 21%-22%
Management reiterated the internal EBITDA margin target of 21%-22% for FY25, with potential revision in Q2 call.
DROPPED
Pen-G and 6-APA meaningful contribution from Q3 FY25
Pen-G and 6-APA facilities will start meaningful contribution from Q3 FY25, with full ramp-up expected by September 2024.
DROPPED
Eugia global revenue run rate of $150M per year
Eugia expects to maintain a global revenue run rate of $150 million per year, with US contributing $100-$110 million.
DROPPED
Biosimilar trastuzumab US filing within 3 months
Trastuzumab biosimilar to be filed with US FDA within the next 3 months, following a successful Type 4 pre-submission meeting.
NEW RISK
Pen-G ramp-up delays
Pen-G plant faced teething problems in Q1; any further delays could impact margin improvement expectations.
NEW RISK
Injectables remediation and FDA compliance
Eugia Unit III remediation cost $9M in Q1; Bhiwadi plant received OAI. Further regulatory actions could disrupt injectable sales.
NEW RISK
US price erosion and competition
Management expects current US pricing scenario to continue; low single-digit price erosion in injectables could pressure margins.
NEW RISK
Biosimilar approval delays
Biosimilar filings with EMA and FDA are subject to regulatory uncertainties; delays could push revenue contribution beyond FY26.
RISK GONE
Eugia 3 OAI status may delay ANDA approvals
Eugia 3 plant classified as OAI; 29 pending ANDAs may be stuck for at least 1 year, impacting injectable growth.
RISK GONE
Biosimilar monetization timeline pushed to 2027-2028
Management expects meaningful biosimilar revenue only by 2027-2028, later than some investor expectations.
RISK GONE
Pen-G ramp-up complexity may delay benefits
Pen-G fermentation is complex; yield optimization will only be addressed by September, posing execution risk.
RISK GONE
Ryzneuta launch in US faces competitive pressure
Management is conservative on Ryzneuta (pegfilgrastim biosimilar) launch, citing multiple competitors and uncertain pricing.
🤫 Topics management stopped discussing
Mentioned in Q1 FY24, Q2 FY24
On track to achieve $560 million globally for Eugia Specialities in FY24, driven by injectable growth.
Fast read
Guidance and risk preview
Management reiterated the internal EBITDA margin target of 21%-22% for FY25, with potential revision in Q2 call.
Pen-G plant faced teething problems in Q1; any further delays could impact margin improvement expectations.
View Risks →